Free Trial

Cadrenal Therapeutics (CVKD) News Today

Cadrenal Therapeutics logo
$16.56 -1.17 (-6.60%)
(As of 11/13/2024 ET)
Analysts Offer Predictions for CVKD Q1 Earnings
Cadrenal Therapeutics (NASDAQ:CVKD) Price Target Raised to $32.00
Cadrenal Therapeutics Advances Tecarfarin Development
Ponte Vedra pharmaceutical company raises $5.1 million
Cadrenal Therapeutics raises $5.1M via at-the-market facility
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin
Cadrenal Therapeutics, Inc. stock logo
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Sees Large Decline in Short Interest
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 18,000 shares, a decrease of 7.2% from the September 15th total of 19,400 shares. Based on an average daily volume of 32,500 shares, the short-interest ratio is currently 0.6 days. Approximately 3.2% of the company's shares are short sold.
Cadrenal Therapeutics, Inc. stock logo
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Shares Sold by Renaissance Technologies LLC
Renaissance Technologies LLC lessened its position in shares of Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Free Report) by 59.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 59,491 shares of the company's stock after selling 88,647 shar
Cadrenal Therapeutics, Inc. stock logo
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Sees Significant Increase in Short Interest
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 19,400 shares, a growth of 22.8% from the August 31st total of 15,800 shares. Approximately 3.4% of the company's stock are short sold. Based on an average daily volume of 25,600 shares, the short-interest ratio is currently 0.8 days.
Cadrenal Therapeutics, Inc. stock logo
Zacks Small Cap Comments on Cadrenal Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:CVKD)
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Free Report) - Equities researchers at Zacks Small Cap issued their Q3 2024 EPS estimates for Cadrenal Therapeutics in a note issued to investors on Monday, September 16th. Zacks Small Cap analyst D. Bautz expects that the company will post earnings of (
Cadrenal Therapeutics, Inc. stock logo
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 15,800 shares, an increase of 295.0% from the August 15th total of 4,000 shares. Based on an average daily volume of 20,200 shares, the short-interest ratio is presently 0.8 days. Approximately 2.8% of the shares of the company are short sold.
Cadrenal Therapeutics Inc CVKD
Get Cadrenal Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

CVKD Media Mentions By Week

CVKD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CVKD
News Sentiment

0.38

0.55

Average
Medical
News Sentiment

CVKD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CVKD Articles
This Week

12

1

CVKD Articles
Average Week

Get Cadrenal Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CVKD) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners